Ranbaxy Lab Peer Comparison

NSE: RANBAXY | BSE: 500359

₹859.80

₹45.80 (5.63%)

As on 01-Apr-2015IST

Market cap

₹36,603 Cr

Revenue (TTM)

₹5,759 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	36,603	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	5,759	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-135.76	414.00	288.22	-371.81	387.35
Net Margin (%)	-2.08	11.23	14.79	-3.93	26.01
RoE (%)	-10.47	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	13.98	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	12,459.73	4,350.50	34.80	--	33.90
Total Income	12,750.46	4,375.84	34.80	--	34.61
Total Expenditure	10,654.56	2,996.79	25.65	--	30.42
EBITDA	1,805.16	1,353.71	9.15	--	3.48
Depreciation	320.25	115.07	2.71	--	1.05
EBIT	1,484.92	1,238.64	6.44	--	2.42
Interest	303.60	269.02	2.51	--	1.10
Other Income	290.74	25.34	0.42	--	0.71
Exceptional Items	-227.16	-473.77	--	--	--
Profit before Tax	1,244.89	521.19	3.93	--	2.03
Provision for Tax	293.90	221.74	1.40	--	0.68
Profit after Tax	950.99	299.45	2.52	--	1.35

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	4,084.33	1,471.02	37.49	--	6.11
Minority Interest	88.95	--	--	--	--
Non-Current Liabilities	3,277.61	2,891.88	5.39	--	0.04
Current Liabilities	8,965.45	1,890.94	24.92	--	15.82
Total Liabilities	16,452.00	6,253.84	67.79	--	22.09

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	6,404.00	3,772.33	47.64	--	5.51
Current Assets	10,012.33	2,481.51	20.15	--	16.45
Total Assets	16,452.00	6,253.84	67.79	--	22.09
Total Debt*	4,901.30	3,492.50	19.14	--	6.41
Net Current Assets	1,046.89	590.57	-4.76	--	0.63
Contingent Liabilities	284.58	46.91	0.71	--	--

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	1,582.10	1,343.83	5.07	--	--
Cash Flow from Investing Activities	-1,820.32	-305.45	-4.60	--	--
Cash from Financing Activities	236.92	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	-1.29	211.82	-0.36	--	0.00

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	18.96	16.20	12.09	--	25.61
ROE (%)	27.53	66.74	14.65	--	24.87
ROA (%)	5.93	4.97	4.06	--	6.42
EBIT Margin (%)	16.82	31.70	26.29	--	12.34
Net Margin (%)	7.46	6.84	7.25	--	3.90
Cash Profit Margin (%)	10.18	9.52	15.04	--	6.56

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	20.63	15.97	65.29	--	21.86
EBIT Growth (%)	19.87	29.05	42.04	--	27.63
Net Profit Growth (%)	132.98	212.90	6.25	--	7.55
EPS Growth (%)	131.75	278.36	6.25	--	7.55
Book Value Growth (%)	42.35	253.45	15.81	--	28.51

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	23.04	17.64	0.00	--	0.00
Price / Book Value	5.24	9.37	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	10.29	7.33	4.36	--	1.71
Market Cap (₹ Cr)	21,262.00	6,555.46	0.00	--	0.00

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	1.21	2.39	0.51	--	1.05
Short term debt to equity ratio	0.70	0.18	0.21	--	0.88
Current Ratio	1.12	1.31	0.81	--	1.04
Quick Ratio	0.81	0.84	0.77	--	0.66
Interest Coverage	5.10	2.94	2.57	--	2.86

	Ranbaxy Lab	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	16.35	17.44	42.51	--	24.27
Asset Turnover	0.78	0.72	0.56	--	1.74
Receivable days	73.69	57.17	120.33	--	81.45
Inventory Days	78.07	67.16	9.04	--	45.36
Payable days	66.78	116.25	535.25	--	134.63
Cash Conversion Cycle	84.98	8.07	-393.94	--	-7.82

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.